Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$236M in Q4 2025 → $322M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Relmada Therapeutics Inc | 15.8% | Trimmed 13% | 7,350,000 | $50.9M |
| C4 Therapeutics Inc | 10.4% | Added 220% | 7,200,000 | $33.6M |
| Cogent Biosciences Inc | 10.4% | Added 9.8% | 865,000 | $33.5M |
| Kodiak Sciences Inc | 6.0% | Added 32% | 500,000 | $19.5M |
| Relay Therapeutics Inc | 5.6% | Added 44% | 970,000 | $18.1M |
| Zentalis Pharmaceuticals Inc | 5.6% | Added 1.9% | 3,700,000 | $17.9M |
| Edgewise Therapeutics Inc | 3.7% | Trimmed 17% | 290,000 | $11.8M |
| Maze Therapeutics Inc | 3.1% | Added 30% | 335,000 | $10M |
| Inventiva Sa | 2.9% | Added 355% | 2,435,000 | $9.2M |
| AN Adlai Nortye Ltd | 2.7% | Trimmed 40% | 764,876 | $8.8M |
| Enliven Therapeutics Inc | 2.5% | New | 160,000 | $8.12M |
| Arrivent Biopharma Inc Call | 2.0% | Added 66% | 183,000 | $6.36M |
| Palisade Bio Inc | 1.9% | Unchanged | 3,000,000 | $6.27M |
| Bioage Labs Inc Call | 1.9% | New | 250,000 | $6.13M |
| Inhibikase Therapeutics Inc | 1.9% | Trimmed 14% | 3,000,000 | $6.09M |
| Adagene Inc | 1.6% | New | 1,250,000 | $5.25M |
| Forte Biosciences Inc | 1.5% | New | 225,000 | $4.78M |
| Rezolute Inc Call | 1.5% | New | 900,000 | $4.68M |
| Inflarx Nv | 1.4% | New | 2,000,000 | $4.48M |
| Assembly Biosciences Inc | 1.4% | New | 160,000 | $4.4M |
| Compass Pathways PLC Call | 1.3% | New | 305,000 | $4.32M |
| Promis Neurosciences Inc | 1.3% | Unchanged | 324,977 | $4.28M |
| Contineum Therapeutics Inc | 1.3% | New | 260,000 | $4.26M |
| Compass Pathways PLC | 1.3% | New | 300,000 | $4.25M |
| Definium Therapeutics Inc | 1.2% | New | 85,000 | $4M |
| Sol-gel Technologies Ltd | 1.2% | Added 68% | 52,000 | $3.86M |
| Bioage Labs Inc | 1.2% | New | 155,000 | $3.8M |
| Scynexis Inc | 1.0% | New | 756,884 | $3.08M |
| PT Proqr Thrapeutics N V | 0.9% | New | 1,511,496 | $2.81M |
| Disc Medicine Inc Call | 0.7% | New | 30,000 | $2.19M |
| Rezolute Inc | 0.7% | New | 403,410 | $2.1M |
| LN Lipocine Inc New | 0.6% | Added 80% | 810,000 | $2.07M |
| Zentalis Pharmaceuticals Inc Call | 0.6% | Added 6.5% | 426,000 | $2.07M |
| C4 Therapeutics Inc Call | 0.6% | New | 400,000 | $1.87M |
| UP Ultragenyx Pharmaceutical In Call | 0.6% | New | 55,000 | $1.84M |
| Cue Biopharma Inc | 0.5% | New | 50,000 | $1.58M |
| Calcimedica Inc | 0.4% | New | 1,244,864 | $1.28M |
| QT Quince Therapeutics Inc | 0.2% | New | 40,375 | $734K |
| Nuvectis Pharma Inc Call | 0.2% | New | 38,700 | $712K |
| Pasithea Therapeutics Corp | 0.2% | Trimmed 52% | 1,000,000 | $515K |
| Inmed Pharmaceuticals Inc | 0.2% | New | 325,000 | $504K |
| Neumora Therapeutics Inc. | 0.1% | New | 100,000 | $170K |
| Nextcure Inc | 0.0% | Trimmed 76% | 64,464 | $103K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| C4 Therapeutics Inc | Added | +4,950,000 | +$23.1M | 10.4% |
| Kalvista Pharmaceuticals Inc | Exited | −985,100 | −$19.8M | — |
| Abivax Sa | Exited | −130,000 | −$14.5M | — |
| Nektar Therapeutics | Exited | −125,000 | −$8.99M | — |
| Enliven Therapeutics Inc | New | +160,000 | +$8.12M | 2.5% |
| Relmada Therapeutics Inc | Trimmed | −1,124,571 | −$7.78M | 15.8% |
| Inventiva Sa | Added | +1,900,000 | +$7.18M | 2.9% |
| Scynexis Inc | Exited | −7,608,695 | −$6.98M | — |
| Kalvista Pharmaceuticals Inc | Exited | −315,000 | −$6.34M | — |
| Bioage Labs Inc | New | +250,000 | +$6.13M | 1.9% |
Showing the 10 largest of 59 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Relmada Therapeutics Inc | Added | +1,774,571 | +$12.4M | 21.6% |
| Nektar Therapeutics | New | +125,000 | +$8.99M | 3.3% |
| AN Adlai Nortye Ltd | New | +1,265,231 | +$8.76M | 3.2% |
| Zentalis Pharmaceuticals Inc | New | +3,631,000 | +$8.5M | 3.1% |
| Terns Pharmaceuticals Inc | Exited | −190,000 | −$7.68M | — |
| Scynexis Inc | New | +7,608,695 | +$6.98M | 2.6% |
| Maze Therapeutics Inc | Trimmed | −232,500 | −$6.94M | 2.8% |
| Relay Therapeutics Inc | New | +672,500 | +$6.69M | 2.5% |
| Tarsus Pharmaceuticals Inc | Exited | −80,000 | −$6.55M | — |
| Kalvista Pharmaceuticals Inc | New | +315,000 | +$6.34M | 2.3% |
Showing the 10 largest of 50 changes.
Loading...
